VolitionRx (NYSE:VNRX) Director Timothy Still Acquires 48,076 Shares

VolitionRx Limited (NYSE:VNRX) Director Timothy Still acquired 48,076 shares of the firm’s stock in a transaction on Tuesday, October 14th. The shares were acquired at an average price of $0.51 per share, with a total value of $24,518.76. Following the completion of the transaction, the director directly owned 1,535,458 shares in the company, valued at approximately $783,083.58. This trade represents a 3.23% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

VolitionRx Trading Down 4.5%

Shares of NYSE VNRX opened at $0.44 on Thursday. VolitionRx Limited has a one year low of $0.40 and a one year high of $0.94. The firm has a market capitalization of $47.34 million, a PE ratio of -1.22 and a beta of 1.27. The business has a 50-day moving average price of $0.63 and a two-hundred day moving average price of $0.61.

Institutional Investors Weigh In On VolitionRx

Several institutional investors and hedge funds have recently added to or reduced their stakes in VNRX. Blair William & Co. IL acquired a new stake in VolitionRx in the 2nd quarter worth approximately $30,000. Northwestern Mutual Wealth Management Co. acquired a new stake in VolitionRx in the 2nd quarter worth approximately $52,000. Silverberg Bernstein Capital Management LLC lifted its holdings in VolitionRx by 42.8% in the 2nd quarter. Silverberg Bernstein Capital Management LLC now owns 200,782 shares of the company’s stock worth $153,000 after purchasing an additional 60,209 shares during the last quarter. Finally, Armistice Capital LLC lifted its holdings in VolitionRx by 3.5% in the 2nd quarter. Armistice Capital LLC now owns 8,493,074 shares of the company’s stock worth $6,455,000 after purchasing an additional 286,644 shares during the last quarter. 8.09% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. HC Wainwright reaffirmed a “buy” rating and set a $2.50 price target on shares of VolitionRx in a research note on Tuesday, September 30th. D. Boral Capital reaffirmed a “buy” rating and set a $5.00 price target on shares of VolitionRx in a research note on Monday, September 29th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $3.50.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.